Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENSET - GENXY -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (142)	2/12/2001 10:53:05 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 200

Genset also intends to end its gene discovery research programs undertaken for the account of pharmaceutical company partners. Almost all of these programs are either completed or will be in the coming months. ...and then start up new partnerships which will lead to profits in a couple years. ?! Well, I guess you have to expect a few of these worthless press releases with Nature and Science doing their thing, and HGP and Celera in the papers today. Wont do a thing for the shares tomorrow. If they do too many of these goofy press releases, I'm going to start thinking that it is all misdirection, and that they'll be selling out alltogether this year. Isn't Genentech sitting on more than a billion cash? And to any of the real, bloated, multibillion dollar pharmas out there, gobbling up poor little Genset can be done for next to nothing. I have a terrible feeling my GENXY is going to be a lousy two bagger in a year or two, and not a long term ten bagger. I'm sticking with my shares for sure, but do not bother with this sort of thing again Mr. Pernet! Pandering to the market makes you look weak. I hope the rest of my companies issue no PRs this week.

To: Mike McFarland who wrote (142)	2/21/2001 2:47:04 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 200

So what's it going to be...the quarterly boilerplate: The Company anticipates that it will continue to incur losses for the foreseeable future; the amount and duration of such losses will depend largely on the level of its continued investment in research and development activities and the timing of future licensing deals on the results of these activities. or a partnership with an industry heavyweight would permit the group to turn a profit as soon as next year Pretty crappy timing with the market going to hell. Good thing I'm a buyer...sellers not having too much fun, and tommorrow will truly suck.